Corium International, Inc. (NASDAQ:CORI) had its price objective upped by Needham & Company LLC from $13.00 to $16.00 in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Corium International from a hold rating to a buy rating and set a $12.00 price target for the company in a research note on Tuesday, October 3rd. Cantor Fitzgerald reaffirmed a buy rating and set a $12.00 price target on shares of Corium International in a research note on Wednesday, September 27th. HC Wainwright initiated coverage on shares of Corium International in a research note on Tuesday, September 26th. They set a buy rating and a $15.00 price target for the company. Jefferies Group LLC set a $10.00 price target on shares of Corium International and gave the stock a buy rating in a research note on Sunday, October 29th. Finally, BidaskClub cut shares of Corium International from a strong-buy rating to a buy rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Corium International has a consensus rating of Buy and a consensus target price of $13.00.

Shares of Corium International (CORI) opened at $11.29 on Monday. Corium International has a 52 week low of $2.67 and a 52 week high of $12.18. The company has a quick ratio of 6.80, a current ratio of 7.04 and a debt-to-equity ratio of 1.89.

TRADEMARK VIOLATION WARNING: “Needham & Company LLC Raises Corium International, Inc. (CORI) Price Target to $16.00” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/23/needham-company-llc-raises-corium-international-inc-cori-price-target-to-16-00.html.

In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $11.05, for a total transaction of $1,657,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 868,100 shares of company stock valued at $9,538,781 in the last ninety days. Insiders own 46.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC acquired a new stake in shares of Corium International during the second quarter worth $3,085,000. State Street Corp acquired a new stake in shares of Corium International during the second quarter worth $1,840,000. Bank of New York Mellon Corp lifted its holdings in shares of Corium International by 33.7% during the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 22,285 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of Corium International during the second quarter worth $563,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Corium International during the second quarter worth $411,000. 89.96% of the stock is owned by institutional investors.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.